On-going Pregnancy Rates from Vitrified Eggs as Good as those From Fresh, Finds Randomised Trial

Article

From the Annual Conference of the European Society of Human Reproduction and Embryology in Rome

Rome, Italy: Embryos derived from oocytes (eggs) cryopreserved by the vitrification method are just as likely to produce an on-going pregnancy as those involving fresh oocytes, the 26th annual meeting of the European Society of Human Reproduction and Embryology heard today. Dr. Ana Cobo, Cryobiology Unit director at Institut Universitari – IVI Valencia, Valencia, Spain, told delegates that the results of her team’s research would make egg donation both easier and safer in the future.

The scientists carried out a randomised clinical trial involving 600 recipients of either freshly-harvested oocytes or those preserved by the vitrification method, where oocytes are flash-frozen after the extraction of water, hence avoiding ice formation. Analysis of the results found that the on-going pregnancy rate in women who had received vitrified oocytes was 43.7% as opposed to 41.7% in the fresh oocyte group. The proportion of top-quality embryos was similar between the two groups, and there was also no difference in age or other demographic characteristics and the incidence of male factor infertility.

“Because we were able to show that there were no differences between the two groups before embryo implantation,” said Dr. Cobo, “we can be certain that the on-going pregnancy rates in both groups were not influenced by any factor other than the method of oocyte preservation. Although there has been considerable circumstantial evidence that cryopreservation by the vitrification method produces results as good as those with freshly-harvested oocytes, until this trial there was still a lack of large randomly-controlled studies in the field.”

The researchers say that their results will have a significant effect on the practice of egg-banking in the future. “Many patients will be able to benefit,” said Dr. Cobo. “For example, there are cancer patients who will be able to preserve their fertility before undergoing treatment that can make them sterile, patients who would be at risk of ovarian hyperstimulation, and those where a semen sample is not immediately available.”

Once an egg donor is recruited and screened she undergoes ovarian stimulation to produce a number of oocytes, which are then retrieved. The oocytes then need to be fertilised by the sperm of the male partner of the recipient and the best embryos thus produced are placed in the uterus of the recipient, whose uterine lining has been previously prepared to be ready to receive the embryo.

When using fresh oocytes, the need for synchronisation of all these procedures is paramount, but not always possible. Egg banking precludes the need to synchronise these timings, which can also be the cause of long delays

“As well as being able to shorten or even eliminate the current long waiting lists, egg banking also offers a safer donation process because it allows oocytes to be quarantined while the absence of any contagious disease in the donor is confirmed,” said Dr. Cobo. “Until now we have been unable to do this with any certainty.”

The scientists now intend to continue their research by following up the progress of babies born after oocyte vitrification. “We need to ascertain that there are no adverse effects on children conceived from cryopreserved oocytes,” said Dr. Cobo, “so we will compare obstetric and neonatal data from babies born after oocyte vitrification with those resulting from the replacement of embryos originating from fresh oocytes. Having made sure that the pregnancies are safe, it is important to ensure that pregnancy outcomes are also free from harm.”

References:

Abstract no: O-225 Wednesday 10.00 hrs CEST (Hall 10, Rooms F & G)

In English and French:

Mary Rice:

Tel: +33 (0)3 21 82 54 44

Mobile: +33 (0)6 68 93 06 50

Email: mary@mrcommunication.org

In English:

Emma Mason

Tel: +44 (0) 1376 563090

Mobile: +44 (0) 7711 296 986

Email: wordmason@mac.com

In English, German, Spanish, French, Swedish

Hanna Hanssen

Tel: + 32 (0)2 269 09 69

Mobile: + 32 (0) 473 35 33 81

Email: hanna@eshre.eu

In Italian and English

Elisa Marcellini

Tel: +39 (0)2 76 11 51 47

Mobile: +39 340 868 96 90

Email: e.marcellini@mdemmedi.com

Press Office: (Sunday 27 June – Wednesday 30 June)

Mary Rice, Emma Mason, Hanna Hanssen, Elisa Marcellini

Recent Videos
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
raanan meyer, md
Fertility counseling for oncology patients | Image Credit: allhealthtv.com
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit: rmanetwork.com
The importance of maternal vaccination | Image Credit: nfid.org.
Haywood Brown, MD | Image credit: © USF Health
Beth Garner, MD, MPH
Related Content
© 2024 MJH Life Sciences

All rights reserved.